Zhang Fan, Wang Jia, Wang Xiaobo, Wei Nan, Liu Haiyang, Zhang Xiaoju
Department of Respiratory Medicine, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Clinical Research Center, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Clin Respir J. 2019 Jan;13(1):23-33. doi: 10.1111/crj.12976.
Tumours are more likely to metastasize after the development of resistance to EGFR-TKIs. CD146 is a multifunctional molecule and is implicated in tumour invasion and metastasis; however, its role in lung cancer has not been clearly established.
Here, we aimed to explore the relationship between CD146 pathway and stem cell phenotype after EGFR-TKI resistance in lung cancer.
EGFR-TKI-resistant cell lines were established by exposing parental cells to erlotinib/gefitinib. The CD146 level was measured by a western blot, RT-PCR and immunocytochemistry fluorescent. Cell migration was examined by the transwell assay and the scratch assay. Stemness phenotype genes were evaluated by RT-PCR and stem cell phenotype was observed by the microsphere formation assay.
CD146 and stemness phenotype genes increased while β-catenin decreased in acquired EGFR-TKI-resistant cell lines. CD146's over-expression induced the up-regulation of stemness-related genes and was inversely correlated with the β-catenin expression, which further increased the migration capability of resistant cancer cells. CD146's knockdown suppressed cell migration and stemness phenotype.
CD146 molecule contributes to the stemness phenotype and migration in EGFR-TKI-resistant cells. CD146 might be a potential therapeutic target for EGFR-TKI-resistant lung cancer or metastasis prevention.
肿瘤在对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)产生耐药性后更易发生转移。CD146是一种多功能分子,与肿瘤侵袭和转移有关;然而,其在肺癌中的作用尚未明确。
在此,我们旨在探讨肺癌中EGFR-TKI耐药后CD146通路与干细胞表型之间的关系。
通过将亲本细胞暴露于厄洛替尼/吉非替尼来建立EGFR-TKI耐药细胞系。通过蛋白质免疫印迹法、逆转录-聚合酶链反应(RT-PCR)和免疫细胞化学荧光法检测CD146水平。通过Transwell实验和划痕实验检测细胞迁移。通过RT-PCR评估干性表型基因,并通过微球形成实验观察干细胞表型。
在获得性EGFR-TKI耐药细胞系中,CD146和干性表型基因增加,而β-连环蛋白减少。CD146的过表达诱导干性相关基因上调,并与β-连环蛋白表达呈负相关,这进一步增加了耐药癌细胞的迁移能力。CD146的敲低抑制了细胞迁移和干性表型。
CD146分子有助于EGFR-TKI耐药细胞的干性表型和迁移。CD146可能是EGFR-TKI耐药肺癌或预防转移的潜在治疗靶点。